Recently Diagnosed or Relapsed? Stop Looking For a Miracle Cure, and Use Evidence-Based Therapies To Enhance Your Treatment and Prolong Your Remission
Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
- You are here:
- Home »
- Blog »
- Multiple Myeloma »
- Myeloma Patients on CAR-T Therapy
Myeloma Patients on CAR-T Therapy
What do myeloma patients say about CAR-T Therapy? Not oncologists or researchers but the actual myeloma patients who received CAR-T cell therapy?
Myeloma patients who have undergone CAR-T cell therapy think differently about the procedure than do oncologists.
CAR-T cell therapy explained. I found this video to give as clear and concise an explanation of CAR-T cell therapy as I’ve seen. And the speaker even touches on CRS aka cytokine release syndrome- the inflammation caused by CAR-T cells.
As clear an explanation as is given here, it is important for the MM patient to remember that, according to the research lined below, that oncologists have a fundamentally different view of outcomes aka side effects than do the MM patients do who actually undergo CAR-T cell therapy.
I am not being critical of conventional oncology. I do not believe that anyone who has not undergone chemo, radiation, an ASCT or CAR-T cell therapy, can truly understand the side effects of that therapy.
I cannot help but wonder if MM patients who are about to undergo CAR-T therapy, if they shouldn’t undergo non-conventional therapies to enhance their immune systems.
Just a thought.
Email me at David.PeopleBeatingCancer@gmail.com if you have any questions about MM.
Thank you,
David Emerson
- MM Survivor
- MM Cancer Coach
- Director PeopleBeatingCancer
Patient-reported outcomes of chimeric antigen receptor T-cell therapy in hematologic malignancies: a systematic review and meta-analysis
“Few studies evaluated patient-reported outcomes (PROs) for patients with hematologic malignancies receiving with Chimeric Antigen Receptor T (CAR-T) cell therapy. We performed a systematic review and meta-analysis to evaluate the benefits of CAR-T cell therapies focused on PROs.
A systematic literature searched from PubMed, Cochrane, and the Web of Science from inception to September 2023. Study selection and data extraction were conducted independently by two reviewers based on pre-specified criteria.
The COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) Risk of Bias checklist was used to evaluate the methodological quality of the included studies. The random-effects model was employed to calculate the combined effect and 95% Confidence intervals.
This study was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline and the protocol was registered with PROSPERO (CRD42024586706).
We identified 20,110 studies. Of those, 15 studies with 16 different PRO measures (PROMs) were included in the meta-analysis. CAR-T cell therapy improved PROs in the six domains of
- general health status,
- pain,
- fatigue,
- depression,
- social function,
- and cognitive function:
from the general health status (SMD: 0.57, 95% CI: 0.34 to 0.81) to cognitive function (SMD: 0.25, 95% CI: 0.14 to 0.37). The current meta-analysis shows that CAR-T cell therapy produces clinically meaningful differences in PROs.
These results suggest that the professional perspective and patient values and preferences should be weighed equally when considering CAR-T cell therapy for hematologic malignancies…
Conclusion
The current meta-analysis indicates that CAR-T cell therapy for hematologic malignancies improves PROs in six domains including general health status, pain, fatigue, depression, social function, and cognitive function.
General health status might be a minimal clinically meaningful improvement from three months after CAR-T cell therapy in patients with hematologic malignancies.
Although there is controversy as to whether CAT-T cell therapy is cost-effective, it has reported efficacy in patients with hematologic malignancies with unmet medical need.
The current meta-analysis adds evidence that CAR-T cell therapy produces clinically meaningful differences in patient-reported outcomes.
These results suggest that the professional’s perspective and patient’s values and preferences should be balanced in determining to use CAR-T cell therapy for patients with hematologic malignancies.”